ImaginAb was seed funded in 2007 by Momentum Biosciences an early-stage venture fund co-founded by Christian Behrenbruch (ImaginAb’s CEO) that was established to accelerate start-up opportunities out of UCLA and Caltech.
In March 2012, ImaginAb closed a $12.5m round of growth capital led by Novartis Venture Funds. Other key investors in the syndicate included Mérieux Developpment, the VC-arm of the Mérieux Group, Zurich-based Nextech Invest (a dedicated oncology fund) and Cycad Group.
